CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic

Bisha Ding1,2, Chang Bao2, Luqi Jin3

  • 1Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Frontiers in Oncology
|July 12, 2021
PubMed

Insights

Calcium/calmodulin-dependent serine protein kinase (CASK) promotes sorafenib resistance in hepatocellular carcinoma (HCC). Inhibiting CASK enhances sorafenib efficacy by promoting apoptosis and autophagy, suggesting CASK as a therapeutic target for HCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Resistance Research

Background:

  • Hepatocellular carcinoma (HCC) treatment is often hindered by drug resistance, particularly to sorafenib.
  • The role of Calcium/calmodulin-dependent serine protein kinase (CASK) in HCC progression and drug resistance remains largely unexplored.

Purpose of the Study:

  • To investigate the functional role of CASK in hepatocellular carcinoma (HCC) and its association with sorafenib resistance.
  • To elucidate the molecular mechanisms underlying CASK's influence on HCC cell death pathways and therapeutic response.

Main Methods:

  • Utilized gain- and loss-of-function strategies to manipulate CASK expression in HCC cells.
  • Employed cell counting kit-8 assay, colony formation assay, flow cytometry, transmission electron microscopy, immunofluorescence, xenograft experiments, and immunohistochemistry.
  • Investigated the involvement of apoptosis and autophagy pathways, including the c-Jun N-terminal kinase (JNK) signaling.

Main Results:

  • CASK expression positively correlated with sorafenib resistance and poor prognosis in HCC patients.
  • CASK inhibition enhanced sorafenib efficacy by promoting apoptosis and autophagy, while CASK overexpression had opposite effects.
  • Both apoptosis and autophagy were implicated in CASK-mediated effects, with autophagy playing a pro-death role, and CASK knockout activated the JNK pathway.

Conclusions:

  • CASK plays a significant role in promoting sorafenib resistance and influencing cell death pathways in HCC.
  • Targeting CASK, potentially through modulating apoptosis and autophagy via the JNK pathway, could overcome sorafenib resistance.
  • CASK represents a promising biomarker and a potential therapeutic target for improving HCC patient outcomes.

Related Concept Videos

Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.7K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside...
12.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.2K